Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)

Locations

3 Belgium sites

Age

> 6 Years

Genotypes

SS, SC

Phase

N/A

Study type

Interventional

Gender

All

Interventions

Other

Compensation

Unknown

About the study

Sickle cell disease is associated with significant morbi-mortality hence the interest in an
early and targeted care. At present, there is no plasmatic marker able to identify infants at
higher risk of developping severe complications later in life. However, recent studies have
demonstrated a correlation between certain complications of the disease and biomarkers of the
endothelial dysfunction characterizing it.

Investigators prospectively followed a cohort of children diagnosed with SCD through the
universal neonatal screening using inflammatory and haemostatic plasmatic markers to study
their annual evolution. Investigators then will evaluate potential associations between these
biological markers and the occurrence of SCD related complications. A secondary objective of
this study is to evaluate the repercussions of therapeutic intervention on these markers.

.

participation requirements

– Patient aged less than 6 months

– Sickle cell syndrome SS, Sβthal or SC confirmed by hemoglobin electrophoresis

– Subjects legal representatives must have signed an informed consent document
indicating that they understand the purpose of and procedures required for the study
and are willing to let participate their child in the study

participation restrictions

– Congenital abnormality other than sickle cell disease except for a
glucose-6-phosphate-deshydrogenase

– Prematurity

– Initiation of the following therapies before enrollment: chronic transfusion regimen
or bone marrow transplantation

Locations

  • Brussels, Belgium, CHU Saint Pierre, 1000
  • Brussels, Belgium, Hôpital Universitaire Des Enfants Reine Fabiola, 1020
  • Brussels, Belgium, HIS - Site Etterbeek-Ixelles, 1050